



Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

**Semi-Annual
Management Report
of Fund Performance
May 31, 2024**

Caution Regarding Forward-looking Statements

Certain portions of this report, including, but not limited to, “Results of Operations” and “Recent Developments”, may contain forward-looking statements about the Fund, including its strategy, risks, expected performance and condition. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar forward-looking expressions or negative versions thereof.

In addition, any statement that may be made concerning future performance, strategies or prospects, and possible future Fund action, is also a forward-looking statement. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about the Fund and economic factors. Accordingly, assumptions concerning future economic and other factors may prove to be incorrect at a future date.

Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made by the Fund. Any number of important factors could contribute to these digressions, including, but not limited to, general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, technological change, changes in government regulations, unexpected judicial or regulatory proceedings, and catastrophic events.

It should be stressed that the above-mentioned list of important factors is not exhaustive. You are encouraged to consider these and other factors carefully before making any investment decisions and you are urged to avoid placing undue reliance on forward-looking statements. Further, you should be aware of the fact that the Fund has no specific intention of updating any forward-looking statements whether as a result of new information, future events or otherwise, prior to the release of the next Management Report of Fund Performance.

Semi-Annual Management Report of Fund Performance as at May 31, 2024

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

This semi-annual management report of fund performance contains financial highlights but does not contain the complete semi-annual financial statements for the investment fund. You can get a copy of the semi-annual financial statements at your request, and at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our website at www.fidelity.ca or SEDAR+ at www.sedarplus.ca.

Securityholders may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure relating to the investment fund.

Management Discussion of Fund Performance

Results of Operations

Fidelity Global Health Care Class (Fund) invests substantially all of its assets in securities of Fidelity Global Health Care Fund (Underlying Fund).

Fidelity Global Health Care Class, Series B, returned 12.5%, after fees and expenses, for the six-month period ended May 31, 2024. The net returns of the other series of the Fund are similar to those of Series B, except for differences attributable to expense structures. During the review period, global equities, as represented by the MSCI World Index, returned 15.5% (in Canadian dollar terms).

Market overview:

Global equities, as broadly measured by the MSCI World Index, returned 15.5% in Canadian dollar terms and 14.9% in U.S. dollar terms, for the six-month period ended May 31, 2024.

Global equities advanced during the review period, as resilient economic data and expectations for interest rate cuts, fuelled by decelerating inflation in developed markets, supported expectations for a soft landing in the global economy. Better-than-expected corporate earnings growth further encouraged investor confidence. However, markets were volatile as inflation remained well above the target range of most developed market central banks. Against this global backdrop, U.S., Japan, and Europe ex-U.K. equities rose. In Europe, equities posted robust returns, supported by resilient economic and corporate data as well as a slew of dovish cues from major central banks. Japanese equities also rose, driven primarily by central bank policy expectations, centred on the Bank of Japan and the U.S. Federal Reserve, accompanied by weakness in the Yen. Emerging markets also ended higher but lagged developed markets amid concerns around China's sluggish economic recovery. Investors were concerned about China's growth prospects in the absence of any meaningful stimulus and a suppressed housing market.

Factors affecting performance:

The Fund's benchmark, MSCI ACWI (All Country World Index) Health Care Index, returned 10.8% (in Canadian dollar terms) for the review period.

The Fund outperformed its benchmark for the review period. The Underlying Fund's investments in the life health care equipment and supplies industry contributed to relative returns, particularly an investment in U.S.-based medical devices manufacturer Boston Scientific and an out-of-benchmark exposure to U.S.-based commercial-stage medical technology company Transmedics Group. The Underlying Fund's investments in the biotechnology industry, including an out-of-benchmark exposure to U.S.-based biotechnology company Karuna Therapeutics and a lack of exposure to a U.S.-based biopharmaceutical company, also contributed to relative returns. Among other industries, a lack of exposure to a U.S.-based pharmaceutical company contributed to relative returns, as did investments in U.S.-based health care facilities provider HCA Healthcare and Belgium-based biopharmaceutical company UCB SA.

In contrast, the Underlying Fund's out-of-benchmark exposure to the personal care products industry and a higher-than-benchmark exposure to the health care providers and services industry detracted from relative returns. In the personal care products industry, an out-of-benchmark exposure to U.K.-based consumer healthcare company Haleon detracted from relative returns. In the health care providers and services industry, investments in U.S.-based home health care services company Humana and U.S.-based health insurance company UnitedHealth Group detracted from relative returns. Among other industries, the Underlying Fund's investments in U.S.-based pharmaceuticals company Eli Lilly and Switzerland-based pharmaceutical company Roche Holding also detracted from relative returns.

At the end of the review period, the Underlying Fund had no exposure to Karuna Therapeutics or Humana.

Portfolio changes:

The Underlying Fund's portfolio manager, Alex Gold, takes a bottom-up approach to stock selection and uses Fidelity's research capabilities to tap global investment opportunities in this sector.

During the review period, the Underlying Fund increased its allocations to the health care equipment and supplies industry and the pharmaceutical industry. In the health care equipment and supplies industry, the portfolio manager initiated a position in UCB SA. In the pharmaceutical industry, the portfolio manager increased exposure to Eli Lilly. The portfolio manager believes these companies have attractive investment growth potential.

In contrast, the Underlying Fund's exposure to the life sciences tools and services industry and the biotechnology industry was decreased. In the life sciences tools and services industry, the portfolio manager reduced exposure to U.S.-based scientific equipment and services company Thermo Fisher Scientific, in favour of what the manager believes, are more attractive opportunities elsewhere. In the biotechnology industry, the portfolio manager reduced exposure to U.S.-based biopharmaceutical company AbbVie.

At the end of the review period, the Underlying Fund had its largest exposure to the pharmaceuticals industry, followed by the health care equipment and supplies industry. The Underlying Fund diverged most from its benchmark's sector weightings by having more exposure to the health care equipment and supplies industry and less exposure to the pharmaceuticals industry.

Recent Developments

Portfolio manager Alex Gold's investment philosophy is based on three pillars: quality, visibility and sustainability. The portfolio manager's bottom-up investment approach seeks to identify health care businesses with superior and sustainable return on invested capital (ROIC), high levels of free cash-flow generation, a good track record and a history of disciplined capital

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Management Discussion of Fund Performance – continued

allocation. The portfolio manager believes the health care sector is highly attractive for investing. The portfolio manager prefers to invest in what the portfolio manager believes to be high-quality companies that are set to benefit from the long-term structural growth drivers in health care: an aging population and increased health care needs. To identify leaders in innovation, the portfolio manager focuses on research and development, which the portfolio manager believes are the backbone of any company's success. This focus enables the portfolio manager to identify companies that the portfolio manager believes are playing a key role in the evolution of health care, ensuring better outcomes for patients and driving down costs for the health system.

Related Party Transactions

Manager and Portfolio Adviser

The Fund is managed by Fidelity Investments Canada ULC (Fidelity). Fidelity is part of a broader collection of companies collectively known as Fidelity Investments.

Fidelity provides or arranges for the provision of all general management and administrative services required by the Fund in its day-to-day operations, bookkeeping, record-keeping and other administrative services for the Fund.

Fidelity is the portfolio adviser to the Fund and it provides investment advisory services to the Fund. Fidelity has entered into sub-advisory agreements with a number of entities including FIL Limited to provide investment advice with respect to all or a portion of the investments of the Fund. The sub-advisors arrange for acquisition and disposition of portfolio investments, including all necessary brokerage arrangements. The Fund pays Fidelity a monthly management and advisory fee for their services, based on the net asset value of each Series, calculated daily and payable monthly. The Fund paid Fidelity management and advisory fees of \$367,000 for the period ended May 31, 2024.

Administration Fee

Fidelity charges the Fund a fixed administration fee in place of certain variable expenses. Fidelity, in turn, pays all of the operating expenses of the Fund, other than certain specified fund costs (e.g. the fees and expenses of the Independent Review Committee, taxes, brokerage commissions and interest charges). The Fund pays an annual rate, which is calculated on a tiered basis, based on the net asset value of each Series, calculated daily and payable monthly. The Fund paid Fidelity administration fees of \$46,000 for the period ended May 31, 2024.

Independent Review Committee, Cross-Trading and In specie Transactions

Independent Review Committee

Fidelity has established an independent review committee (IRC) that acts as an impartial and independent committee to review and provide recommendations or, if appropriate, approvals respecting conflict of interest matters referred to it by Fidelity. The IRC prepares, at least annually, a report of its activities for securityholders of the Fund. The report is available at www.fidelity.ca or at the securityholder's request at no cost by contacting Fidelity, using the contact information available on the final page of this document.

Cross-Trading and In specie Transactions

The Fund received the approval and standing instructions from the IRC in order to:

- (i) engage in cross-trading, which is a form of interfund trading. A cross-trade occurs when the Fund purchases or sells portfolio securities from or to another Fund, a U.S. fund or a separately managed account, through a broker;
- (ii) permit the Fund, in certain circumstances, to purchase and redeem Fund securities in consideration for securities rather than cash of another investment fund not governed by NI 81-102, or a separately managed account, managed by Fidelity.

For each of the transactions in (i) and (ii) above, the IRC's standing instructions require Fidelity to act in accordance with its associated policies and procedures and applicable law, and comply with the conditions in each of the exemptive relief orders received, which, in the case of cross-trading, requires additional periodic reporting to the Ontario Securities Commission. The standing instructions also require that investment decisions in respect of these transactions (a) are free from any influence by an entity related to Fidelity and without taking into account any consideration relevant to an entity related to Fidelity; (b) represent the business judgment of Fidelity uninfluenced by considerations other than the best interests of the Fund; (c) comply with the applicable policies and procedures of Fidelity; and (d) achieve a fair and reasonable result for the Fund.

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the period end of the years shown. This information is derived from the Fund's audited annual and/or unaudited semi-annual financial statements. Please see the front page for information about how you can obtain the Fund's annual or semi-annual financial statements.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series A

	Six months ended May 31, 2024	2023	2022	2021	2020	2019
The Series' Net Assets per Security ^A						
Net assets, beginning of period ^B	\$ 32.90	\$ 33.19	\$ 33.51	\$ 29.36	\$ 27.00	\$ 24.18
Increase (decrease) from operations:						
Total revenue	—	—	—	—	—	—
Total expenses (excluding distributions)	(.44)	(.81)	(.80)	(.81)	(.72)	(.62)
Realized gains (losses)	.84	1.43	1.29	1.17	1.23	1.23
Unrealized gains (losses)	3.67	(1.11)	(1.34)	3.87	1.76	2.04
Total increase (decrease) from operations ^B	4.07	(.49)	(.85)	4.23	2.27	2.65
Distributions:						
From net investment income (excluding dividends)	—	—	—	—	—	—
From dividends	—	—	—	—	—	—
From capital gains	—	—	—	—	—	—
Return of capital	—	—	—	—	—	—
Total distributions ^{B,C}	—	—	—	—	—	—
Net assets, end of period ^B	\$ 36.97	\$ 32.90	\$ 33.19	\$ 33.51	\$ 29.36	\$ 27.00
Ratios and Supplemental Data						
Net asset value (000s) ^{D,E}	\$ 3,171	\$ 3,193	\$ 4,580	\$ 6,152	\$ 5,227	\$ 4,644
Securities outstanding ^F	85,775	97,049	137,971	183,588	178,024	171,970
Management expense ratio ^{F,G}	2.50%	2.50%	2.51%	2.53%	2.55%	2.53%
Management expense ratio before waivers or absorptions ^{F,G}	2.57%	2.57%	2.58%	2.60%	2.63%	2.60%
Trading expense ratio ^H	.04%	.03%	.05%	.04%	.06%	.03%
Portfolio turnover rate ^I	3.14%	9.74%	23.51%	13.78%	16.66%	21.00%
Net asset value per security, end of period	\$ 36.9689	\$ 32.9044	\$ 33.1921	\$ 33.5072	\$ 29.3610	\$ 27.0050

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series B

	Six months ended May 31, 2024	2023	2022	2021	2020	2019
The Series' Net Assets per Security ^A						
Net assets, beginning of period ^B	\$ 34.21	\$ 34.42	\$ 34.66	\$ 30.31	\$ 27.81	\$ 24.85
Increase (decrease) from operations:						
Total revenue	—	—	—	—	—	—
Total expenses (excluding distributions)	(.41)	(.76)	(.74)	(.77)	(.68)	(.59)
Realized gains (losses)	.87	1.59	1.34	1.41	1.27	1.25
Unrealized gains (losses)	3.82	(1.13)	(1.02)	2.71	1.92	2.15
Total increase (decrease) from operations ^B	4.28	(.30)	(.42)	3.35	2.51	2.81
Distributions:						
From net investment income (excluding dividends)	—	—	—	—	—	—
From dividends	—	—	—	—	—	—
From capital gains	—	—	—	—	—	—
Return of capital	—	—	—	—	—	—
Total distributions ^{B,C}	—	—	—	—	—	—
Net assets, end of period ^B	\$ 38.48	\$ 34.21	\$ 34.42	\$ 34.66	\$ 30.31	\$ 27.81
Ratios and Supplemental Data						
Net asset value (000s) ^{D,D}	\$ 22,768	\$ 21,583	\$ 24,658	\$ 24,662	\$ 11,375	\$ 10,011
Securities outstanding ^F	591,651	630,896	716,335	711,568	375,296	359,990
Management expense ratio ^{F,G}	2.26%	2.25%	2.25%	2.31%	2.33%	2.33%
Management expense ratio before waivers or absorptions ^{F,G}	2.32%	2.31%	2.32%	2.39%	2.40%	2.40%
Trading expense ratio ^H	.04%	.03%	.05%	.04%	.06%	.03%
Portfolio turnover rate ^I	3.14%	9.74%	23.51%	13.78%	16.66%	21.00%
Net asset value per security, end of period	\$ 38.4832	\$ 34.2109	\$ 34.4233	\$ 34.6608	\$ 30.3087	\$ 27.8121

Financial Highlights – continued

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series F

	Six months ended May 31, 2024		2023	Periods ended November 30,			2019
	2022	2021	2020				
The Series' Net Assets per Security ^A							
Net assets, beginning of period ^B	\$ 43.07	\$ 43.14	\$ 42.99	\$ 37.18	\$ 33.73	\$ 29.80	
Increase (decrease) from operations:							
Total revenue	—	—	—	—	—	—	
Total expenses (excluding distributions)	(.26)	(.48)	(.47)	(.50)	(.43)	(.36)	
Realized gains (losses)	1.10	1.83	1.55	1.81	1.48	1.47	
Unrealized gains (losses)	4.81	(1.51)	(1.43)	2.70	1.94	3.01	
Total increase (decrease) from operations ^B	5.65	(.16)	(.35)	4.01	2.99	4.12	
Distributions:							
From net investment income (excluding dividends)	—	—	—	—	—	—	
From dividends	—	—	—	—	—	—	
From capital gains	—	(.28)	(.03)	—	—	—	
Return of capital	—	—	—	—	—	—	
Total distributions ^{B,C}	—	(.28)	(.03)	—	—	—	
Net assets, end of period ^B	\$ 48.72	\$ 43.07	\$ 43.14	\$ 42.99	\$ 37.18	\$ 33.73	
Ratios and Supplemental Data							
Net asset value (000s) ^{E,D}	\$ 31,017	\$ 28,805	\$ 34,199	\$ 22,025	\$ 8,104	\$ 2,836	
Securities outstanding ^E	636,671	668,844	792,683	512,316	217,999	84,090	
Management expense ratio ^{F,G}	1.13%	1.14%	1.14%	1.20%	1.20%	1.20%	
Management expense ratio before waivers or absorptions ^{F,G}	1.16%	1.17%	1.17%	1.24%	1.24%	1.23%	
Trading expense ratio ^H	.04%	.03%	.05%	.04%	.06%	.03%	
Portfolio turnover rate ^I	3.14%	9.74%	23.51%	13.78%	16.66%	21.00%	
Net asset value per security, end of period	\$ 48.7197	\$ 43.0685	\$ 43.1444	\$ 42.9923	\$ 37.1768	\$ 33.7323	

Financial Highlights Footnotes

- ^A This information is derived from the Fund's audited annual and/or unaudited interim financial statements. The net assets attributable to securityholders per security presented in the financial statements may differ from the net asset value calculated for fund pricing purposes. An explanation of these differences can be found in the notes to financial statements.
- ^B Net assets and distributions are based on the actual number of securities outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of securities outstanding over the financial period. This table is not intended to be a reconciliation of beginning to ending net assets per security.
- ^C Distributions were paid in cash or reinvested in additional securities of the Fund, or both, and excludes any applicable distributions of management fee reduction to securityholders.
- ^D Prior period amounts may have been adjusted.
- ^E This information is provided as at period end of the year shown.
- ^F Management expense ratio is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset values during the period, including the Fund's pro-rata share of estimated expenses incurred in any underlying investment fund, if applicable.
- ^G Effective November 1, 2014, the manager of the Fund has waived a portion of its administration fee and as of the date of the MRFP has continued to provide the Fund with such waivers. The manager may terminate the waiver at any time, at its sole discretion. It is not known when such waivers will be terminated.
- ^H The trading expense ratio represents total commissions, other portfolio transaction costs and dividends and interest expense on securities sold short expressed as an annualized percentage of daily average net asset value during the period, including the Fund's pro-rata share of estimated trading costs incurred in any underlying investment fund, if applicable.
- ^I The Fund's portfolio turnover rate indicates how actively the Fund's portfolio adviser manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher the Fund's portfolio turnover rate in a year, the greater the trading costs payable by the Fund in the year, and the greater chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high portfolio turnover rate and the performance of the Fund. The portfolio turnover rate is calculated based on the lesser of purchases or sales of securities divided by the weighted average market value of portfolio securities owned by the Fund, excluding short-term securities. The portfolio turnover rate includes any proceeds from a short sale in the value of sales of securities and the cost of covering a short sale in the value of purchases of securities. For periods greater than six months, but less than a full fiscal year, the portfolio turnover rate is annualized. The portfolio turnover rate excludes any adjustment for in-kind transactions.

Management and Advisory Fees

Fidelity serves as manager and investment advisor of the Fund. The Fund pays Fidelity a monthly management and advisory fee for its services, based on the net asset value of each Series, calculated daily and payable monthly. Fidelity uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Fund securities, as well as for the general investment management expenses. Dealer compensation represents cash commissions paid by Fidelity to registered dealers during the period and includes upfront deferred sales charge and trailing commissions. This amount may, in certain circumstances, exceed 100% of the fees earned by Fidelity during the period. For new Funds or Series the amounts presented may not be indicative of longer term operating periods.

	Management Fees (%)	Dealer Compensation (%)	Investment management, administration and other (%)
Series A	2.000	24.26	75.74
Series B	1.850	54.05	45.95
Series F	0.850	-	100.00

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.


Past Performance

The performance information shown assumes that all distributions made by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges, or income taxes payable by any investor that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.


Year-by-Year Returns

The following bar chart shows the Fund's annual performance for each of the years shown, and illustrates how the Fund's performance was changed from year to year. In percentage terms, the bar chart shows how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year. For each Series in the Year-by-Year Returns table below, the most recent returns stated are for the current six month period.


Series A



Series B



Series F



Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

Summary of Investment Portfolio as at May 31, 2024

Sector Mix		
	% of Fund's Net Assets as at May 31, 2024	% of Fund's Net Assets as at November 30, 2023
Pharmaceuticals	27.8	27.2
Health Care Equipment & Supplies	26.7	19.1
Health Care Providers & Services	20.8	20.2
Life Sciences Tools & Services	13.2	18.4
Biotechnology	6.9	9.0
Personal Care Products	1.4	1.5
Others (Individually Less Than 1%)	0.5	1.2
Cash and Cash Equivalents	2.7	3.6
Net Other Assets (Liabilities)	0.0	(0.2)

Comparative balances, as applicable, have been reclassified to align with current period presentation.

Geographic Mix		
	% of Fund's Net Assets as at May 31, 2024	% of Fund's Net Assets as at November 30, 2023
United States of America	71.8	76.3
Denmark	9.3	6.6
United Kingdom	7.9	6.0
France	3.0	1.8
Switzerland	2.6	4.4
Belgium	1.7	0.0
Japan	1.0	0.0
Others (Individually Less Than 1%)	0.0	1.5
Cash and Cash Equivalents	2.7	3.6
Net Other Assets (Liabilities)	0.0	(0.2)

Top Issuers		% of Fund's Net Assets
1.	UnitedHealth Group, Inc.	8.9
2.	Novo Nordisk A/S	7.1
3.	Eli Lilly & Co.	6.1
4.	AstraZeneca PLC	5.9
5.	Boston Scientific Corp.	5.3
6.	Stryker Corp.	4.6
7.	Thermo Fisher Scientific, Inc.	4.5
8.	ICON PLC	4.0
9.	HCA Holdings, Inc.	3.9
10.	Regeneron Pharmaceuticals, Inc.	3.5
11.	Elevance Health, Inc.	3.5
12.	Roche Holding AG	3.1
13.	Fidelity U.S. Money Market Investment Trust — Series O	2.6
14.	Intuitive Surgical, Inc.	2.6
15.	Sonova Holding AG	2.4
16.	AbbVie, Inc.	2.3
17.	McKesson Corp.	2.3
18.	IQVIA Holdings, Inc.	2.2
19.	Cigna Group	2.2
20.	Convatec Group PLC	2.0
21.	EssilorLuxottica SA	1.7
22.	UCB SA	1.7
23.	Coloplast A/S	1.7
24.	Insulet Corp.	1.6
25.	Sanofi SA	1.5
		<u>87.2</u>

Total Fund Net Assets \$56,956,000

Where applicable, the information in the above tables includes the Fund's pro-rata share of the investment in any Fidelity managed underlying fund.

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. The most recent annual report, semi-annual report, quarterly report, fund facts document or simplified prospectus for the investment fund and/or underlying fund is available at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments Canada ULC, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our web site at www.fidelity.ca or SEDAR+ at www.sedarplus.ca.



Fidelity Capital Structure Corp.
407 2nd Street S.W., Suite 820
Calgary, Alberta T2P 2Y3

Manager and Registrar

Fidelity Investments Canada ULC
483 Bay Street, Suite 300
Toronto, Ontario M5G 2N7

Custodian

State Street Trust Company of Canada
Toronto, Ontario

Visit us online at

www.fidelity.ca

or call Fidelity Client Services
at 1-800-263-4077

Fidelity's mutual funds are sold by registered Investment Professionals. Each Fund has a simplified prospectus, which contains important information on the Fund, including its investment objective, purchase options, and applicable charges. Please obtain a copy of the prospectus, read it carefully, and consult your Investment Professional before investing. As with any investment, there are risks to investing in mutual funds. There is no assurance that any Fund will achieve its investment objective, and its net asset value, yield, and investment return will fluctuate from time to time with market conditions. Investors may experience a gain or loss when they sell their securities in any Fidelity Fund. Fidelity Global Funds may be more volatile than other Fidelity Funds as they concentrate investments in one sector and in fewer issuers; no single Fund is intended to be a complete diversified investment program. Past performance is no assurance or indicator of future returns. There is no assurance that either Fidelity Canadian Money Market Fund, Fidelity Canadian Money Market Investment Trust, Fidelity U.S. Money Market Fund or Fidelity U.S. Money Market Investment Trust will be able to maintain its net asset value at a constant amount. The breakdown of Fund investments is presented to illustrate the way in which a Fund may invest, and may not be representative of a Fund's current or future investments. A Fund's investments may change at any time.

®Fidelity Investments is a registered trademark of Fidelity Investments Canada ULC.